News for Nymox Pharmaceutical Corporation - Google Finance

NYMOX PHARMACEUTICAL CORPORATION : Nymox Reports First Quarter ...

Wed, 15 May 2013 15:56:19 GMT

NYMOX PHARMACEUTICAL CORPORATION : Nymox Reports First Quarter ...
4-traders (press release) - May 15, 2013

Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population.

Nymox Pharmaceutical Corporation (NYMX) Releases Quarterly Earnings Results - Mideast Time

NYMOX PHARMACEUTICAL CORPORATION : Nymox Reports on Symposium ...

Tue, 07 May 2013 18:11:25 GMT

NYMOX PHARMACEUTICAL CORPORATION : Nymox Reports on Symposium ...
4-traders (press release) - May 7, 2013

HASBROUCK HEIGHTS, NJ (May 6, 2013) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American ...

NYMOX PHARMACEUTICAL CORPORATION : Nymox Announces Completion ...

Fri, 03 May 2013 16:52:38 GMT

NYMOX PHARMACEUTICAL CORPORATION : Nymox Announces Completion ...
4-traders (press release) - May 3, 2013

HASBROUCK HEIGHTS, NJ (May 3, 2013) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of patient enrollment in the Company's final pivotal U.S.

NYMOX PHARMACEUTICAL CORPORATION : Nymox NX-1207 Symposium ...

Tue, 30 Apr 2013 17:55:37 GMT

NYMOX PHARMACEUTICAL CORPORATION : Nymox NX-1207 Symposium ...
4-traders (press release) - Apr 30, 2013

HASBROUCK HEIGHTS, NJ (April 30, 2013) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce further information about the upcoming Symposium on NX-1207 to be held on May 5 at 3 p.m.

NYMOX PHARMACEUTICAL CORPORATION : Nymox Announces First Patient ...

Fri, 26 Apr 2013 22:03:30 GMT

NYMOX PHARMACEUTICAL CORPORATION : Nymox Announces First Patient ...
4-traders (press release) - Apr 26, 2013

HASBROUCK HEIGHTS, NJ (April 23, 2013) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that the first patient has been enrolled in the Company's Study NX02-0022.

Alzheimer`s Disease Therapeutics and Diagnostics: Global Markets

Thu, 23 May 2013 07:26:55 GMT

Alzheimer`s Disease Therapeutics and Diagnostics: Global Markets
Sacramento Bee - 19 hours ago

The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.

US/Canada daily earnings hits & misses May 15 - 1815 ET

Wed, 15 May 2013 12:01:45 GMT

US/Canada daily earnings hits & misses May 15 - 1815 ET
Reuters - May 15, 2013

... SOFTWARE & EDP SERVICES USD 0.18 0.19 0.01 33.0 33.2 0.3 NYMOX PHARMACEUTICAL CORP Q1 DRUGS CAD -0.05 -0.03 0.02 0.8 0.8 0.1 OMNITEK ENGINEERING CORP Q1 MACHINERY USD -0.01 -0.01 0.00 675.0 349.3 -325.7 OVASCIENCE ...

Nymox Pharmaceutical Corp Announces New Positive Results In Phase 3 Repeat Injection Study Of NX-1207 for BPH

Tue, 22 Jan 2013 17:30:00 GMT

Nymox Pharmaceutical Corp Announces New Positive Results In Phase 3 Repeat Injection Study Of NX-1207 for BPH
Reuters Key Development - Jan 22, 2013

Nymox Pharmaceutical Corp Announces New $15 Million Equity Financing Commitment

Thu, 20 Dec 2012 17:00:09 GMT

Nymox Pharmaceutical Corp Announces New $15 Million Equity Financing Commitment
Reuters Key Development - Dec 20, 2012

Nymox Pharmaceutical Corp's NX-1207 Prostate Cancer Trial Receives Positive Interim Safety Review From Independent Data Monitoring Committee

Thu, 20 Sep 2012 13:41:00 GMT

Nymox Pharmaceutical Corp's NX-1207 Prostate Cancer Trial Receives Positive Interim Safety Review From Independent Data Monitoring Committee
Reuters Key Development - Sep 20, 2012